RichLegg/E+ via Getty Images Introduction & Investment Thesis I initiated a "hold" rating on Align Technology (NASDAQ:ALGN) on March 1, where my thesis was predicated on my belief that the stock could remain under pressure as its operating margin had been declining, even though the company was showing signs of recovering revenue growth. Since then, the medical device company known for its Invisalign product has underperformed the S&P 500 (SPY) and Nasdaq 100 (QQQ) and is down 19% since the time of my writin ...

Align Technology, Inc's (ALGN) successful efforts to broaden the Invisalign portfolio are poised to bring significant growth in the upcoming quarters. Continued expansion into new regions and new manufacturing facilities appears optimistic. A sound financial stability is beneficial for the stock as well. Meanwhile, the adverse macroeconomic impacts on its operations and excessive reliance on a single platform raise concerns.In the past year, this Zacks Rank #3 (Hold) company has lost 27.6% compared with 2.6 ...

You’ve come to the right place if you’re looking for secular growth stocks. This article explores 3D printing stocks, poised to benefit from an annualized industry growth rate of 23.5% until 2030.The depth of application of 3D printing has become known to many. However, for some reason, numerous 3D printing stocks remain grossly undervalued. As such, I decided to delve into the 3D printing arena to pick out three best-in-class 3D printing equities.Considering the above, I framed my screening methodology aro ...

The Zacks Medical - Dental Supplies industry in the Medical sector has shown a positive trend in 2024 as product sales continue to rise. The recent uptick in the sale of dental products and services can be primarily linked to the lifting of limitations associated with the pandemic over the last few years. Also, the major players in the industry have been taking initiatives like cost-cutting and price improvement to improve their margins, post the pandemic. Factors fueling the dental market include the preva ...

Wall Street’s impressive bull run in 2023, which reversed the nightmare of 2022 has continued in the first half of 2024. U.S. stock markets’ northward journey is likely to continue in the second half of this year. Year to date, the three major stock indexes — the Dow, the S&P 500 and the Nasdaq Composite — have rallied 3.1%, 13% and 16.4%, respectively.Peak inflation is far behind us. The labor market remains resilient. The global supply-chain system has been restoring slowly since last year as U.S. corpora ...

Align Technology’s (ALGN) robust product line, consistent focus on international markets and strategic alliances bolster our confidence in the stock. The stock carries a Zacks Rank #2 (Buy) currently.Align Technology is strategically capturing the growing malocclusion market, one of the most prevalent clinical dental conditions in the world. According to Align Technology’s May 2023 data, the condition currently affects approximately 60% to 75% of the global population. The company estimates that there are a ...

Core Viewpoint - Align Technology has experienced a decline of approximately 18.7% in share price over the past month, underperforming the S&P 500, raising questions about the potential for a breakout or continued negative trend leading up to the next earnings release [1] Financial Performance - The company reported adjusted earnings per share of $2.14 for Q1 fiscal 2024, reflecting a 17.6% increase year-over-year and surpassing the Zacks Consensus Estimate by 8.1% [2] - Revenues for the quarter increased by 5.8% year-over-year to $997.4 million, exceeding the Zacks Consensus Estimate by 2.6% [3] - The Clear Aligner segment saw revenues rise 3.5% year-over-year to $817.3 million, driven by strong volume growth in APAC and EMEA regions, while Imaging Systems & CAD/CAM Services revenues increased by 2.4% to $180.2 million [4] Margins and Expenses - Gross profit for Q1 was $697.8 million, up 5.6% year-over-year, but gross margin contracted by 9 basis points to 70.0% due to a 6.1% increase in the cost of net revenues [5] - SG&A expenses rose by 2.8% to $451.8 million, and R&D expenses increased by 5% to $91.9 million, with operating income growing 15.4% to $154.1 million and operating margin expanding by 130 basis points to 15.5% [5] Cash Position and Stock Repurchase - At the end of Q1 2024, Align Technology had cash and cash equivalents of $865.8 million, down from $937.4 million at the end of Q4 [6] - The company repurchased approximately 1.1 million shares at an average price of $230.13, with $650 million remaining for stock repurchase under its January 2023 program [7] Guidance - Align Technology updated its full-year 2024 revenue guidance to an increase of 6-8% year-over-year, with the Zacks Consensus Estimate for 2024 revenues at $4.04 billion [8] - For Q2 2024, the company anticipates revenues between $1.03 billion and $1.05 billion, aligning with the Zacks Consensus Estimate of $1.03 billion [8] Market Sentiment - Estimates for Align Technology have trended downward over the past month, indicating a shift in market sentiment, although the company holds a Zacks Rank 2 (Buy), suggesting an expectation of above-average returns in the coming months [9][11]

Align Technology (ALGN) has been beaten down lately with too much selling pressure. While the stock has lost 9.2% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator t ...

Align Technology’s (ALGN) robust product line, balanced growth across all channels and consistent focus on international markets to drive growth bolster our confidence in the stock. The stock carries a Zacks Rank #2 (Buy) currently.Align Technology is strategically capturing the growing malocclusion market, one of the most prevalent clinical dental conditions in the world. According to Align Technology’s 2023 data, malocclusion currently affects approximately 60% to 75% of the global population. The company ...

Is Align Technology Stock A Buy? scyther5 / Getty Images Align Technology (NASDAQ: ALGN), most notably the makers of Invisalign aligners specializes in orthodontic devices and restorative treatment has been through a whirlwind the past 2 years, with its stock price dropping 60% since its high in September 2021.2024 has also seen its challenges, after the stock increased 20% its has worked its way back down to about even for the year. For long term investors, does today’s price create a nice entry into Ali ...